Stem Cell Research Articles
Stem cell therapy is a fascinating field of medicine with enormous amounts of research devoted to its advancement. We have pulled together a group of relevant scientific publications for those who are interested in a deeper review. Below is a list stem cell research articles to help you gain additional insight into the ongoing studies. Research conclusions bring clarity into persisting stem cell myths.
Adipose-Derived Adult Stem Cells and New Technique for Intracavernosal Injection for Erectile Dysfunction: Novel Approach to Treat Diabetes Mellitus. Erectus Shot Technique
PUBLISHED in Integrative Molecular Medicine Medicine, 2016, Vol 3(2) AUTHOR Carlos Mercado, MD
Four types of patients: DM, ED due to prostatectomy and radiation, Peyronie’s disease, and ED organic cause/aging/vascular. Patients filled out the intensity score questionnaire before and after procedure. Both reported better erections in the morning, firmer, and better response to PDI5 inhibitors for which they were not responders prior to the treatment. This might be due to stem cells induced regeneration of the cavernous nerve and endothelial cells enhancing the nitric oxide production hence improved response to PDI-5 inhibitors.
PUBLISHED on The Journal of Arthroscopic and Related Surgery, 2015 AUTHORS Jack M. Bert, M.D.
PUBLISHED on BioMed Research International by Jaewoo Pak et al., 2014. AUTHORS Jaewoo Pak, Jung Hun Lee and Sang Hee Lee.
PUBLISHED on Wiley Online Library by AlphaMed Press, 2014. AUTHORS Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, Kim JE, Shim H, Shin JS, Shin IS, Ra JC, Oh S, Yoon KS.
KEYWORDS Adipose-tissue derived mesenchymal stem cells; Cartilage regeneration; Intra-articular injection; Osteoarthritis.
PUBLISHED on Digital Journal by The American Academy of Orthopaedic Surgeons (AAOS), 2014.
- There was no abnormal (ectopic) tissue formation or “clinically important” safety issues identified.
- There was “significantly increased meniscal volume,” determined by an MRI in 24 percent of the patients in the low-dose injection group (A) and six percent of the high-dose injection group (B) at one year. There was no statistical increase in meniscal volume at two years.
- No patients in the control group (non-MSC group) met the 15 percent threshold for increased meniscal volume.
- Patients with osteoarthritis experienced a reduction in pain in the stem cell treatment groups; there was no reduction in pain in the control (non-MSC group).
PUBLISHED in The Journal of Bone & Joint Surgery Inc., 2014. AUTHORS; ; ; ; ; .
Methods: A total of fifty-five patients at seven institutions underwent a partial medial meniscectomy. A single superolateral knee injection was given within seven to ten days after the meniscectomy. Patients were randomized to one of three treatment groups: Group A, in which patients received an injection of 50 × 106 allogeneic mesenchymal stem cells; Group B, 150 × 106 allogeneic mesenchymal stem cells; and the control group, a sodium hyaluronate (hyaluronic acid/hyaluronan) vehicle control. Patients were followed to evaluate safety, meniscus regeneration, the overall condition of the knee joint, and clinical outcomes at intervals through two years. Evaluations included sequential magnetic resonance imaging (MRI).
Results: No ectopic tissue formation or clinically important safety issues were identified. There was significantly increased meniscal volume (defined a priori as a 15% threshold) determined by quantitative MRI in 24% of patients in Group A and 6% in Group B at twelve months post meniscectomy (p = 0.022). No patients in the control group met the 15% threshold for increased meniscal volume. Patients with osteoarthritic changes who received mesenchymal stem cells experienced a significant reduction in pain compared with those who received the control, on the basis of visual analog scale assessments.
Conclusions: There was evidence of meniscus regeneration and improvement in knee pain following treatment with allogeneic human mesenchymal stem cells. These results support the study of human mesenchymal stem cells for the apparent knee-tissue regeneration and protective effects.
PUBLISHED on CNN.com, 2013. AUTHORS
PUBLISHED in The New England Journal of Medicine by the Finnish Degenerative Meniscal Lesion Study (FIDELITY) Group, 2013. AUTHORS Raine Sihvonen, M.D., Mika Paavola, M.D., Ph.D., Antti Malmivaara, M.D., Ph.D., Ari Itälä, M.D., Ph.D., Antti Joukainen, M.D., Ph.D., Heikki Nurmi, M.D., Juha Kalske, M.D., and Teppo L.N. Järvinen, M.D., Ph.D.
METHODS: We conducted a multicenter, randomized, double-blind, sham-controlled trial in 146 patients 35 to 65 years of age who had knee symptoms consistent with a degenerative medial meniscus tear and no knee osteoarthritis. Patients were randomly assigned to arthroscopic partial meniscectomy or sham surgery. The primary outcomes were changes in the Lysholm and Western Ontario Meniscal Evaluation Tool (WOMET) scores (each ranging from 0 to 100, with lower scores indicating more severe symptoms) and in knee pain after exercise (rated on a scale from 0 to 10, with 0 denoting no pain) at 12 months after the procedure.
RESULTS: In the intention-to-treat analysis, there were no significant between-group differences in the change from baseline to 12 months in any primary outcome. The mean changes (improvements) in the primary outcome measures were as follows: Lysholm score, 21.7 points in the partial-meniscectomy group as compared with 23.3 points in the sham-surgery group (between-group difference, −1.6 points; 95% confidence interval [CI], −7.2 to 4.0); WOMET score, 24.6 and 27.1 points, respectively (between-group difference, −2.5 points; 95% CI, −9.2 to 4.1); and score for knee pain after exercise, 3.1 and 3.3 points, respectively (between-group difference, −0.1; 95% CI, −0.9 to 0.7). There were no significant differences between groups in the number of patients who required subsequent knee surgery (two in the partial-meniscectomy group and five in the sham-surgery group) or serious adverse events (one and zero, respectively).
CONCLUSIONS: In this trial involving patients without knee osteoarthritis but with symptoms of a degenerative medial meniscus tear, the outcomes after arthroscopic partial meniscectomy were no better than those after a sham surgical procedure. (Funded by the Sigrid Juselius Foundation and others; ClinicalTrials.gov number, NCT00549172.)
PUBLISHED in The Transplantation Journal, 2013. AUTHORS Orozco, Lluis; Munar, Anna; Soler, Robert; Alberca, Mercedes; Soler, Francesc; Huguet, Marina; Sentís, Joan; Sánchez, Ana; García-Sancho, Javier
METHODS: Twelve patients with chronic knee pain unresponsive to conservative treatments and radiologic evidence of osteoarthritis were treated with autologous expanded bone marrow MSCs by intra-articular injection (40×10 cells). Clinical outcomes were followed for 1 year and included evaluations of pain, disability, and quality of life. Articular cartilage quality was assessed by quantitative magnetic resonance imaging T2 mapping.
RESULTS: Feasibility and safety were confirmed, and strong indications of clinical efficacy were identified. Patients exhibited rapid and progressive improvement of functional indices that approached 65% to 78% by 1 year. This outcome compares favorably with the results of conventional treatments. Additionally, quantification of cartilage quality by T2 relaxation measurements demonstrated a highly significant decrease of poor cartilage areas (on average, 27%), with improvement of cartilage quality in 11 of the 12 patients.
CONCLUSIONS: MSC therapy may be a valid alternative treatment for chronic knee osteoarthritis. The intervention is simple, does not require hospitalization or surgery, provides pain relief, and significantly improves cartilage quality.
PUBLISHED on millenniummedicaltechnologies.com, 2013. AUTHORS David Angeloni
PUBLISHED in Philippine Daily Inquirer, 2013. AUTHORS Cheche V. Moral
Philippines – The Department of Health and some medical organizations are calling for a clampdown on hospitals, clinics and centers offering stem cell treatments. But instead of being discouraged, one of stem cell therapy’s vocal advocates and practitioners in the country said she welcomes the move.
PUBLISHED on fda.gov, 2014.
CHAPTER I–FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER L–REGULATIONS UNDER CERTAIN OTHER ACTS ADMINISTERED BY THE FOOD AND DRUG ADMINISTRATION
PART 1271–HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED PRODUCTS
PUBLISHED in Circulation Research by American Heart Association, 2007. AUTHORS Jeffrey M. Gimble, Adam J. Katz, Bruce A. Bunnell
KEYWORDS adipose tissue, adult stem cells, bone marrow stromal cell, differentiation, tissue engineering
PUBLISHED in Experimental Biology and Medicine, 2008. AUTHORS Hazel Tapp, Edward N. Hanley Jr., Joshua C. Patt, Helen E. Gruber
KEYWORDS adipose-derived stem cells, orthopaedic tissue regeneration, cell-surface markers, differentiation
PUBLISHED in Journal of American Society of Plastic Surgeons, 2012. AUTHORS Gir, Phanette M.D.; Oni, Georgette M.D.; Brown, Spencer A. Ph.D.; Mojallal, Ali M.D., Ph.D.; Rohrich, Rod J. M.D.
PUBLISHED in Molecular Biology of the Cell, 2002. AUTHORS Patricia A. Zuk, Min Zhu, Peter Ashjian, Daniel A. De Ugarte, Jerry I. Huang, Hiroshi Mizuno, Zeni C. Alfonso, John K. Fraser, Prosper Benhaim and Marc H. Hedrick
PUBLISHED on Huffington Post, 2013. AUTHORS Robin L. Smith
PUBLISHED in Discovery Medicine, 2010. AUTHORS Tracey L. Bonfield, Arnold I. Caplan
PUBLISHED in International Journal of COPD, 2010. AUTHORS Tillie L Hackett, Darryl A Knight, and Don D Sin
COPD, stem cell therapy, epithelial repair, regenerative medicine
PUBLISHED in The Journal of Cell Therapy, 2013. AUTHORS J. Michalek, Z. Kristkova, J. Skopalik, Z. Dudasova, A. Darinskas, R. Moster
PUBLISHED on PRWeb, 2013.
Orthopedic surgery specialists highlight relief from arthritis through stem cells.